ELIGIBILITY FOR
ONCOLYTIC VIRUS THERAPY
Two separate questions with two different answers: T-VEC eligibility (defined, assessable) versus clinical trial eligibility (trial-specific, requires direct contact). Tumour accessibility is the first filter.
analyticsAt a Glance
- check_circleT-VEC is approved for injectable, unresectable melanoma lesions β specific location criteria apply
- check_circlePatients with severe immunocompromise may not be eligible due to infection risk from live viruses
- check_circleTrial eligibility varies β prior immunotherapy, tumour size, and performance status are key factors
- check_circleCancerFax can identify specific oncolytic virus programmes and eligibility requirements globally
Two Separate Eligibility Questions
T-VEC eligibility is defined and assessable in a single consultation. Clinical trial eligibility is trial-specific β common themes exist, but cutoffs, prior treatment requirements, and tumour accessibility criteria vary. Finding out whether a specific trial is relevant requires contacting that specific trial site.
T-VEC (Approved)
Unresectable melanoma with injectable cutaneous, subcutaneous, or nodal lesions. No severe immunocompromise. Defined by OPTiM trial and FDA label. Assessable by any melanoma oncologist familiar with T-VEC.
Clinical Trials
Trial-specific criteria: accessible tumour, adequate performance status, confirmed histological diagnosis, adequate organ function, no severe immunodeficiency. Cutoffs vary by trial and enrollment phase.
Key Eligibility Factors
Tumour Accessibility
The single most critical factor. T-VEC requires injectable lesions. PVSRIPO requires stereotactic catheter access. HCC programmes require image-guided percutaneous access. No accessible injectable tumour usually means no intratumoral option.
Immune Status
Live replication-competent viruses require caution in severely immunocompromised patients. High-dose corticosteroids, active HIV with low CD4, significant post-transplant immunosuppression β all require case-by-case evaluation.
Household Contact Considerations
Patients with pregnant, immunocompromised, or neonatal household members need specific pre-treatment planning for T-VEC contact precautions. Manageable in most situations.
Prior Treatment History
Combination trials may exclude prior checkpoint inhibitor progressors. First-line trials exclude prior systemic therapy. Requirements change as trials advance through enrollment phases.
Geographic Access
Most advanced trials run at major academic centres. A biologically eligible patient six hours from the nearest trial site faces a practical barrier that official criteria don't address.
Frequently Asked Questions
Eligibility Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Assessing Your Eligibility?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.